10:28 AM EDT, 07/31/2025 (MT Newswires) -- AbbVie ( ABBV ) raised its full-year outlook on Thursday as the biopharmaceutical company recorded second-quarter results above market expectations, driven by strong revenue growth from its Skyrizi and Rinvoq immunology drugs.

Per-share adjusted earnings are now set to come in between $11.88 and $12.08 for 2025, up from its previous guidance of $11.67 to $11.87. The guidance includes a $0.55 headwind related to acquired in-process research and development and milestone expenses incurred year-to-date through the second quarter. The current consensus on FactSet is for non-GAAP EPS of $11.95.

Revenue is pegged at about $60.5 billion, representing an increase of $800 million and a "relatively neutral" foreign-exchange impact, Chief Financial Officer Scott Reents said on an earnings call, according to a FactSet transcript. The Street is looking for $60.05 billion.

"AbbVie ( ABBV ) delivered another outstanding quarter with strong performance from our diversified growth platform," Chief Executive Robert Michael said in a statement. "We're entering the second half of the year with substantial momentum and are once again raising our full-year outlook."

The company reported adjusted EPS of $2.97 for the June quarter, up from $2.65 the year before and ahead of the Street's view for $2.88. Revenue improved 6.6% to $15.42 billion, topping the average analyst estimate on FactSet for $15.03 billion. The stock was up 2.2% in Thursday trade.

Global sales from the immunology portfolio climbed 9.5% to $7.63 billion, as gains of 62% and 42% in Skyrizi and Rinvoq helped counter a 58% drop in Humira. "We anticipate Humira access in the US will continue to decrease throughout the second half of this year, as more plans select exclusionary formularies for existing patients," Chief Commercial Officer Jeff Stewart said on the call.

In the oncology segment, revenue rose 2.6% to $1.68 billion, aided by a 24% jump in ovarian cancer medication Elahere. The neuroscience division logged revenue growth of 24% to $2.68 billion, while the aesthetics portfolio fell 8% to $1.28 billion. Eye care sales decreased 3.9% to $514 million.

For the ongoing three-month period, AbbVie ( ABBV ) anticipates adjusted EPS to be in a range of $3.24 to $3.28 and revenue of roughly $15.5 billion, Reents told analysts. The market is currently estimating non-GAAP EPS of $3.24 and sales of $15.43 billion.

Price: 193.88, Change: +4.57, Percent Change: +2.41